Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by argenx SE

< Previous 1 2 Next >
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx Highlights 2024 Strategic Priorities
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx Reports Third Quarter 2023 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx announces closing of global offering
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx announces full exercise of underwriters’ option to purchase additional ADSs
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx raises $1.1 billion in gross proceeds in a global offering
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx announces launch of proposed global offering
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
Tickers ARGX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback